A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...
A total of 135 participants were randomly assigned to receive inebilizumab (300-mg infusions on days 1 and 15 and week 26) or ...
Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...
Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...
More than half the women in the treat-to-target group conceived within 3 months vs a median of 6.5 months for those in the ...
November 18, 2024, Press Release from Lima Memorial Health System: Lima Memorial Health System is proud to announce that the ...
WASHINGTON -- Rheumatoid arthritis (RA) patients who achieved sustained remission had better long-term outcomes than those ...
Oral presentation at ACR highlights safety and efficacy data from the Phase 1 trial of umbilical cord outer lining-derived stem cells (ULSCs) ...
Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens ...
The first poster demonstrates proof-of-concept data that Aqtual's therapy selection test can predict treatment response in patients with RA. The second poster provides an interim analysis from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback